Eruptive keratoacanthomas associated with dupilumab therapy
- PMID: 34608625
- DOI: 10.1111/bjd.20781
Eruptive keratoacanthomas associated with dupilumab therapy
Abstract
We would like to present the case of eruptive keratoacanthomas associated with dupilumab therapy, which occurred in an 85-year-old woman receiving biologic therapy for the treatment of atopic dermatitis. With the increasing prevalence of Dupilumab usage, this is an important potential complication of which clinicians should be aware.
© 2021 British Association of Dermatologists.
References
-
- Kong HH, Cowen EW, Azad NS et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56:171-2.
-
- Antonov NK, Nair KG, Halasz CL. Transient eruptive keratoacanthomas associated with nivolumab. JAAD Case Rep 2019; 5:342-5.
-
- Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-15.
-
- He C, Carter A. The metabolic prospective and redox regulation of macrophage polarization. J Clin Cell Immunol 2015; 6:371.
-
- Goudie DR, D’Alessandro M, Merriman B et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet 2011; 43:365-9.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical